Please login to the form below

Algeta

This page shows the latest Algeta news and features for those working in and with pharma, biotech and healthcare.

He has held roles for Keryx Biopharmaceutical, Algeta ASA and AVEO Oncology.

Bayer CEO Dekkers points to 'outstanding' pharma growth

9bn it paid for the drug's developer Algeta last December.
Bayer buys Chinese consumer care company

Bayer buys Chinese consumer care company. Acquires Dihon Pharmaceutical as Algeta takeover closes. ... year. By the extended deadline of February 26 the company had agreements to acquire a little over 97 per cent of Algeta's stock.
Bayer agrees $2.9bn deal for Algeta to get Xofigo control

Bayer agrees $2.9bn deal for Algeta to get Xofigo control. Raises initial offer to buy Norweigan pharma company. ... Bayer has reached an agreement to buy Norwegian pharma company Algeta after raising its offer to around $2.9bn.
Bayer offers $2.4bn to buy Xofigo partner Algeta

Bayer offers $2.4bn to buy Xofigo partner Algeta. Norwegian firm says negotiations still at 'an early stage'. ... One unanswered question is whether Algeta has some other hidden gems in its pipeline.
EU approval for Bayer’s prostate cancer drug

Bayer acquired Xofigo from Norwegian company Algeta in 2009. The deal granted full commercialisation rights in Europe to Bayer while in the US Bayer co-promotes the drug with Algeta.

More from news
Approximately 4 fully matching, plus 9 partially matching documents found.

Pharma deals during June 2014

Bayer paid 50m ($68m) upfront payment with further milestones in return for global rights which should complement Xofigo (from the acquisition of Algeta).
Pharma deals during November 2013

Algeta, has been noted as being rather ungenerous, with room for upping the offer. ... Assuming this acquisition goes through, this buys out the previous deal with Algeta under which there was US co-promotion for 50 per cent of in-country profits, plus
Deal Watch table for November 2013

Hyperlipidemia. 2, 600. Algeta / Bayer. Acquisition. Buys out deal for Xofigo radiotherapeutic for.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Targovax appoints chief financial officer

He also brings experience from cancer biotech Algeta ASA, and management consulting expertise from McKinsey &Company's pharma and healthcare practice.
Targovax appoints Oystein Soug as CEO

He has previously served as chief financial officer for Algeta, a Norwegian oncology biotech that was bought by Bayer in 2014, and spent six years at Orkla, a Norwegian consumer goods
Algeta execs join Targovax

Algeta execs join Targovax. Anna-Kirsti Aksnes and Tina Madsen join the firm. ... Norway's Targovax has added to its senior team with the appointment of two executives from Algeta.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Add my company

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?: What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma: Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies: Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...